Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenomedullin in Acute Non-embolic Ischemic Stroke
jRCT2051190092Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fispemifene in brain infarction (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Serious adverse events (SAE) and NIHSS. Started Jan 2020; status: active, not recruiting.
02
Drugs
fispemifene
03
Conditions
brain infarction
Beyond the preview
Go deeper on jRCT2051190092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190092.